Prediction of tumor-reactive T cell receptors from scRNA-seq data for personalized T cell therapy
C. L. Tan,K. Lindner,T. Boschert,Z. Meng,A. Rodriguez Ehrenfried,A. De Roia,G. Haltenhof,A. Faenza,F. Imperatore,L. Bunse,J. M. Lindner,R. P. Harbottle,M. Ratliff,R. Offringa,I. Poschke,M. Platten,E. W. Green
DOI: https://doi.org/10.1038/s41587-024-02161-y
IF: 46.9
2024-03-08
Nature Biotechnology
Abstract:The identification of patient-derived, tumor-reactive T cell receptors (TCRs) as a basis for personalized transgenic T cell therapies remains a time- and cost-intensive endeavor. Current approaches to identify tumor-reactive TCRs analyze tumor mutations to predict T cell activating (neo)antigens and use these to either enrich tumor infiltrating lymphocyte (TIL) cultures or validate individual TCRs for transgenic autologous therapies. Here we combined high-throughput TCR cloning and reactivity validation to train predicTCR, a machine learning classifier that identifies individual tumor-reactive TILs in an antigen-agnostic manner based on single-TIL RNA sequencing. PredicTCR identifies tumor-reactive TCRs in TILs from diverse cancers better than previous gene set enrichment-based approaches, increasing specificity and sensitivity (geometric mean) from 0.38 to 0.74. By predicting tumor-reactive TCRs in a matter of days, TCR clonotypes can be prioritized to accelerate the manufacture of personalized T cell therapies.
biotechnology & applied microbiology